1999 •
Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction
Authors:
E. Magnus Ohman, Paul W. Armstrong, Harvey D. White, Christopher B. Granger, Robert G. Wilcox, W. Douglas Weaver, W. Brian Gibler, Amanda Stebbins, Cresha Cianciolo, Robert M. Califf, Eric J. Topol
Abstract:
Troponin T has been used successfully to risk stratify patients with acute coronary syndromes, but the utility of this approach using a rapid bedside assay in patients undergoing thrombolysis for ST-segment elevation acute myocardial infarction has not been assessed in a large population. We assessed whether a point-of-care, qualitative troponin T test at enrollment could independently risk-stratify patients randomized to receive alteplase or reteplase in the GUSTO-III trial. Complete troponin T data were available for 12,666 patients (84%) enr (...)
Troponin T has been used successfully to risk stratify patients with acute coronary syndromes, but the utility of this approach using a rapid bedside assay in patients undergoing thrombolysis for ST-segment elevation acute myocardial infarction has not been assessed in a large population. We assessed whether a point-of-care, qualitative troponin T test at enrollment could independently risk-stratify patients randomized to receive alteplase or reteplase in the GUSTO-III trial. Complete troponin T data were available for 12,666 patients (84%) enrolled at 550 hospitals. The primary end point was mortality at 30 days, and the predictive ability of an elevated baseline troponin T level was analyzed (after adjustment for baseline characteristics) with multiple logistic regression. Patients with an elevated troponin T result at enrollment (8.9%) had significantly higher mortality at 30 days (unadjusted 15.7% vs 6.2% for negative patients; p = 0.001), which persisted even after adjustment for age, heart rate, location of infarction, Killip class, and systolic blood pressure. In a multivariable regression model, a positive troponin T result added independently to the prediction of 30-day mortality (chi-square 46, p = 0.001). A positive result with qualitative troponin T testing on admission is an independent marker of higher 30-day mortality. Troponin T testing could be a valuable addition to the evaluation strategy for patients with acute myocardial infarction. (Read More)
E.Magnus Ohman, Paul W Armstrong, Harvey D White, Christopher B Granger, Robert G Wilcox, W.Douglas (...)
The American Journal of Cardiology ·
1999
Internal medicine |
Cardiology |
We have placed cookies on your device to help make this website and the services we offer better. By using this site, you agree to the use of cookies. Learn more